Active ETF

Putnam BioRevolution ETF (Class A)  (SYNB)

Investing in companies that are leveraging innovation within biology

Harnessing the biorevolution for investors

The revolution in biology and life sciences is unleashing new potential for innovation across many sectors, creating opportunities for investors.

Read more

NAV as of 04/12/24


Market data all data below as of 04/12/24

Closing market price $29.55
30-day median bid-ask spread 0.23%
Day high $29.55
Day low $29.55
Premium/Discount -0.02%
30-day average trading volume 135
Net assets and outstanding shares Download CSV

How to buy Putnam ETFs

Putnam ETFs can be purchased and sold the same way you would buy or sell a stock — through most self-directed brokers or with the guidance of your advisor. Opening an online, self-directed brokerage account provides investors with:

  • Accessibility to a variety of investment products
  • Tools to help you build and optimize your portfolio
  • Flexibility and freedom of managing your investment portfolio
See available brokerages Learn about Putnam active ETFs

ETF facts as of 03/31/24

Inception date
Total net assets
Total expense ratio
Open to new investors
Turnover (fiscal year-end)
Dividend frequency
Number of holdings
Fiscal year-end


Putnam BioRevolution ETF seeks long term capital appreciation.

Strategy and process

  • Pursues transformative growth across sectorsThe economic impact of the biology revolution is spreading beyond health care, with potential to transform multiple sectors and drive investment opportunities.
  • Collaborative research processA benchmark-agnostic approach leverages unique, integrated insights of Putnam sector analysts and the Sustainable Equity team.
  • Concentrated portfolioThe manager seeks outperformance by investing in 30-50 high-conviction stocks selected through disciplined portfolio construction and risk management.

Management team

William C. Rives, CFA

Portfolio Manager, Analyst

11 years in industry

11 years at Putnam Investments

See full profile


Fund information

Fact Sheet (PDF)

Legal documents

Annual Report (PDF)
Semiannual Report (PDF)

Related/Investment insights

What is the biorevolution?
The revolution in biology and life sciences is unleashing new potential for innovation across many sectors, creating opportunities for investors.

ESG materiality | Analyzing the growing role of ESG factors in executive compensation
A rising number of S&P 500 companies are now tying ESG metrics to executive pay. Explore insights on how this impacts corporate goals and investment opportunities.

ESG Metrics | Impact report of sustainable investing strategies
Putnam Investments is pleased to share our 2023 Sustainability and Impact Report.


  • Total return (%) as of 03/31/24

Annualized Total return (%) as of 03/31/24

Annualized performance 1 yr. 3 yrs. 5 yrs. Life (inception: 09/29/22 )
Net asset value 13.67% -- -- 15.43%
Market price 13.86% -- -- 15.50%
S&P 500 Index 29.88%11.49%15.05%--

Current performance may be lower or higher than the quoted past performance, which cannot guarantee future results. Share price, principal value, and return will vary, and you may have a gain or loss when you sell your shares. Performance assumes reinvestment of distributions and does not account for taxes. Returns for periods of less than one year are not annualized. Market performance is determined using the bid/ask midpoint at 4:00 p.m. Eastern time. Market performance does not represent the returns you would receive if you traded shares at other times throughout the day.

Shares of any ETF are bought and sold at market price (not NAV), may trade at a discount or premium to NAV, and are not individually redeemed from the fund. Brokerage commissions will reduce returns.

The fund has limited public trading history.


Performance snapshot

  Net asset value Market price
1 mt. as of 03/31/24 2.47% 2.48%
YTD as of 04/12/24 1.52% 1.55%


Record date 12/07/23
Ex-date 12/06/23
Payable date 12/11/23
Income $0.0211
Extra income --
Short-term cap. gain --
Long-term cap. gain --

Historical premium/discount

Number of days at premium --
Number of days at NAV --
Number of days at discount --


Portfolio holdings

Full portfolio holdings Download XLSX
Thermo Fisher Scientific 7.33%
Danaher Corp 6.95%
Nvidia Corp 6.87%
Bio-Rad Laboratories 5.37%
Alphabet 5.14%
Novozymes A/S - B Shares 4.41%
Corteva 4.38%
AbbVie 4.20%
Ascendis Pharma A/S 3.94%
Eli Lilly 3.54%
Top 10 holdings, percent of portfolio 52.14%

Sector weightings as of 02/29/24

Health care 54.60%
Materials 20.40%
Information technology 6.87%
Consumer staples 5.65%
Communication services 5.14%
Cash and net other assets 3.59%
Consumer discretionary 3.32%
Industrials 0.43%

Sectors will vary over time.

Equity statistics as of 02/29/24

Median market cap $19.03B
Weighted average market cap $331.51B
Price to book 3.64
Price to earnings 32.59

The S&P 500® Index is an unmanaged index of common stock performance. You cannot invest directly in an index.

Consider these risks before investing: Biology revolution companies face intense competition and potentially rapid product obsolescence. Biology revolution companies may be adversely affected by the loss or impairment of intellectual property rights and other proprietary information or changes in government regulations. The potential for an increased amount of required disclosure or lack of access to proprietary scientific information could negatively impact the performance of these companies. Investments in small and/or midsize companies increase the risk of greater price fluctuations. Growth stocks may be more susceptible to earnings disappointments, and value stocks may fail to rebound. The value of investments in the fund's portfolio may fall or fail to rise over extended periods of time for a variety of reasons, including general economic, political, or financial market conditions; investor sentiment and market perceptions; government actions; geopolitical events or changes; and factors related to a specific issuer, geography, industry, or sector. These and other factors may lead to increased volatility and reduced liquidity in the fund's portfolio holdings. As a non-diversified fund, the fund invests in fewer issuers and is more vulnerable than a more broadly diversified fund to fluctuations in the values of the securities it holds. Our investment techniques, analyses, and judgments may not produce the outcome we intend. The investments we select for the fund may not perform as well as other securities that we do not select for the fund. We, or the fund's other service providers, may experience disruptions or operating errors that could have a negative effect on the fund. You can lose money by investing in the fund.